Citius Pharmaceuticals Inc vs Okta, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while Okta, Inc. trades at $148.74 (market cap $26.13B). The key difference: Okta, Inc. is far larger — about 1305.8× Citius Pharmaceuticals Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | OKTA | |
|---|---|---|
Market Cap | $20.01M | $26.13B |
Sector | Health | Technology |
52-Week High | $1.82 | $154.62 |
52-Week Low | $0.48 | $62.93 |
Enterprise Value | $16.23M | $23.95B |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Okta trades at $150.04, down 0.48% today, near its pivot point of $150 with bullish moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding expectations. Revenue growth is robust, rising to $2.61B in 2025, while the firm achieved GAAP profitability with net income of $28M, a significant turnaround from prior losses. Recent news highlights Okta's acquisition of Permiso Security to enhance AI-driven identity threat detection, positioning it in the expanding cybersecurity market.
Outlook is positive with analyst consensus at Buy (72.55%) and a $129.71 price target, though current price exceeds this. Opportunities include sustained revenue growth and margin expansion, while risks involve high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Institutional activity shows mixed signals, with some funds increasing stakes amid the stock's 55.6% YTD gain.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →